Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9797715 | 0.83 | PDGFRB (0.42) | EGFRKMT2APDGFRBPDGFRARAB9A | |
| SCHEMBL3367827 | 0.82 | EGFR (0.49) | EGFRKMT2AMEN1HTTLMNA | |
| SCHEMBL554880 | 0.79 | ALDH1A1 (0.50) | KMT2APDGFRBPDGFRARAB9AKDM4E | |
| SCHEMBL15941521 | 0.79 | PDGFRB (0.47) | KMT2AMEN1LMNAMAOAPDGFRB | |
| SCHEMBL13510928 | 0.79 | PDGFRB (0.50) | PDGFRBPDGFRAMAPTRAB9AKDM4E | |
| SCHEMBL29953405 | 0.79 | ESR2 (0.54) | KMT2AMEN1LMNAPDGFRBPDGFRA | |
| SCHEMBL1002550 | 0.79 | HTT (0.46) | KMT2AHTTLMNAMAOAPDGFRB | |
| SCHEMBL2446728 | 0.79 | ESR2 (0.54) | KMT2AMEN1LMNAPDGFRBPDGFRA | |
| SCHEMBL30668491 | 0.77 | MEN1 (0.60) | EGFRKMT2AMEN1HTTLMNA | |
| SCHEMBL10979440 | 0.77 | MEN1 (0.60) | EGFRKMT2AMEN1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-6657065-B2 | Which are useful as microsomal triglyceride transfer protein (MTP) inhibitors | PFIZER INC | 2003-12-02 | — | — | US | disclosed |
| US-20020161233-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-10-31 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6417367-B1 | THAT ARE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS USEFUL FOR TREATING HYPERCHOLESTEROLEMIA FOR EXAMPLE; FEWER SYNTHESIS STEPS, STARTING MATERIALS ARE AN ACYL HALIDE AND M-NITROANILINE | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020042516-A1 | Methods of making quinoline amides | TOM NORMA J (US) | 2002-04-11 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161233-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | EGFR 4755/4885KMT2A 1557/4885MEN1 2262/4885 |
| US-20020042516-A1 | Methods of making quinoline amides | CETP, MTTP, LCAT | EGFR 4755/4885KMT2A 1557/4885MEN1 2262/4885 |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | EGFR 3005/4885KMT2A 3250/4885MEN1 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.